CoChat

Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?

Open access
Wagner, Dimitrios Laurin, Peter, Lena, Schmueck-Henneresse, Michael · 2021 · Gene Therapy

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

Abstract

The dichotomic nature of the adaptive immune response governs the outcome of clinical gene therapy. On the one hand, neutralizing antibodies and cytotoxic T cells can have a dramatic impact on the efficacy and safety of human gene therapies. On the other hand, regulatory T cells (Treg) can promote tolerance toward transgenes thereby enabling long-term benefits of in vivo gene therapy after a single administration. Pre-existing antibodies and T cell immunity has been a major obstacle for in vivo gene therapies with viral vectors. As CRISPR-Cas9 gene editing advances toward the clinics, the technology’s inherent immunogenicity must be addressed in order to guide clinical treatment decisions. This review summarizes the recent evidence on Cas9-specific immunity in humans—including early results from clinical trials—and discusses the risks for in vivo gene therapies. Finally, we focus on solutions and highlight the potential role of Cas9-specific Treg cells to promote immune tolerance. As a “beneficial alliance” beyond Cas9-immunity, antigen-specific Treg cells may serve as a living and targeted immunosuppressant to increase safety and efficacy of gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41434-021-00232-2

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Suppressive actions of regulatory T cells. Regulatory T cells (Treg) are activated following recognition of specific antigens presented by antigen-presenting cells. However, Treg cells also exert a suppressive function irrespective of their antigen-specificity termed as bystander suppression. The mechanism of actions underlying the suppressive function of Tregs can be direct or indirect. Treg cells present with very high basal expression of high affinity CD25, enabling privileged consumption of the IL-2 growth factor and thereby depriving and weakening surrounding conventional effector T cells (Teff) cells. Further, Treg cells mediate specific suppression by depleting peptide-MHC class II-molecule complexes matching their TCR from the surface of antigen-presenting cells via trans-endocytosis and subsequent degradation. As opposed to boosting Teff cells by co-stimulatory signals, Treg cells carry molecules, which were classified as co-inhibitory receptors: e.g., CTLA-4 has high affinity to CD80/CD86 and thereby outcompetes co-stimulatory signals via CD28. Further, Treg cells can disrupt pro-inflammatory mechanisms by eliminating effector cells. Direct cell contact with Treg cells can also be fatal for the respective target cell by induction of the Fas-mediated pathway of apoptosis through ligation by Fas-ligand. In addition, Treg cells use perforin/granzyme dependent cytotoxicity to kill target cells accompanied by adhesion via CD18. Treg cells can also induce suppressive properties in adjacent cells by secreting soluble factors thereby inducing an infectious tolerance. For instance, human Treg cells secrete latent TGFβ thereby promoting a suppressive milieu, as well as shedding of soluble TNFα receptor II, which can neutralize TNFα and prevents its pro-inflammatory signaling. Notably, Tregs can also modulate their environment by secretion of IL-10. IL-2, interleukin 2; CD25, IL-2 receptor α chain; MHC, major histocompatibility complex; TCR, T cell receptor; CTLA-4, cytotoxic T-lymphocyte-associated Protein 4; CD80/CD86, B7, B7-2 type I membrane protein; CD28, co-stimulatory receptor for CD80/86; CD18, Integrin β-2; TGFβ, transforming growth factor; TNFα, tumor necrosis factor; IL-10, interleukin 10.
Fig. 1 Suppressive actions of regulatory T cells. Regulatory T cells (Treg) are activated following recognition of specific antigens presented by antigen-presenting cells. However, Treg cells also exert a suppressive function irrespective of their antigen-specificity termed as bystander suppression. The mechanism of actions underlying the suppressive function of Tregs can be direct or indirect. Treg cells present with very high basal expression of high affinity CD25, enabling privileged consumption of the IL-2 growth factor and thereby depriving and weakening surrounding conventional effector T cells (Teff) cells. Further, Treg cells mediate specific suppression by depleting peptide-MHC class II-molecule complexes matching their TCR from the surface of antigen-presenting cells via trans-endocytosis and subsequent degradation. As opposed to boosting Teff cells by co-stimulatory signals, Treg cells carry molecules, which were classified as co-inhibitory receptors: e.g., CTLA-4 has high affinity to CD80/CD86 and thereby outcompetes co-stimulatory signals via CD28. Further, Treg cells can disrupt pro-inflammatory mechanisms by eliminating effector cells. Direct cell contact with Treg cells can also be fatal for the respective target cell by induction of the Fas-mediated pathway of apoptosis through ligation by Fas-ligand. In addition, Treg cells use perforin/granzyme dependent cytotoxicity to kill target cells accompanied by adhesion via CD18. Treg cells can also induce suppressive properties in adjacent cells by secreting soluble factors thereby inducing an infectious tolerance. For instance, human Treg cells secrete latent TGFβ thereby promoting a suppressive milieu, as well as shedding of soluble TNFα receptor II, which can neutralize TNFα and prevents its pro-inflammatory signaling. Notably, Tregs can also modulate their environment by secretion of IL-10. IL-2, interleukin 2; CD25, IL-2 receptor α chain; MHC, major histocompatibility complex; TCR, T cell receptor; CTLA-4, cytotoxic T-lymphocyte-associated Protein 4; CD80/CD86, B7, B7-2 type I membrane protein; CD28, co-stimulatory receptor for CD80/86; CD18, Integrin β-2; TGFβ, transforming growth factor; TNFα, tumor necrosis factor; IL-10, interleukin 10.CC BY · PubMed Central
Fig. 2 Immunological risk for anti-Cas9 T cell-mediated rejection of gene edited cells/tissues. CRISPR-Cas9 in vivo gene therapy requires Cas9 expression. Intracellular protein degradation processes lead to peptide presentation of Cas9 fragments on the cellular surface of gene-edited cells that may be recognized by SpCas9-reactive T cells. An excessive effector T cell (Teff) response could impact success of gene therapy. However, in vitro studies demonstrate anti-SpCas9 CD4+ Treg cells could inhibit the proliferation and function of anti-Cas9 Teff cells at high Treg to Teff ratios. Potential solution: Enhancing anti-Cas9 Treg cell responses prior to or during in vivo CRISPR-Cas9 gene-therapy.
Fig. 2 Immunological risk for anti-Cas9 T cell-mediated rejection of gene edited cells/tissues. CRISPR-Cas9 in vivo gene therapy requires Cas9 expression. Intracellular protein degradation processes lead to peptide presentation of Cas9 fragments on the cellular surface of gene-edited cells that may be recognized by SpCas9-reactive T cells. An excessive effector T cell (Teff) response could impact success of gene therapy. However, in vitro studies demonstrate anti-SpCas9 CD4+ Treg cells could inhibit the proliferation and function of anti-Cas9 Teff cells at high Treg to Teff ratios. Potential solution: Enhancing anti-Cas9 Treg cell responses prior to or during in vivo CRISPR-Cas9 gene-therapy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 111 references

Cited by

See all 65

Metadata

Authors
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M.
Affiliations
Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
Venue
Gene Therapy
Published
2021-02-11
Volume
28
Issue
9
Pages
549-559
ISSN
  • 0969-7128 (ISSN-L)
  • 1476-5462
OpenAlex
W3128665302
Cited by
63
References
110
Citations by year
2026: 12 · 2025: 17 · 2024: 8 · 2023: 11 · 2022: 11 · 2021: 4
FWCI
0.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Gene Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
  • Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
  • Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
Funders
  • European Commission (825392, HORIZON2020)
  • Bundesministerium für Bildung und Forschung
  • Berlin Institute of Health
  • Einstein Centrum für Regenerartive Therapien, Charité-Universitätsmedizin Berlin
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
regulatory T cells, CRISPR/Cas9 genome editing, immune tolerance, in vivo gene therapy, viral vector gene therapy, neutralizing antibodies, cytotoxic T lymphocytes, immunogenicity, clinical trials, immunosuppression
MeSH terms
Gene Editing, Humans, Immune Tolerance, Genetic Therapy, T-Lymphocytes, Regulatory, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy? https://app.cochat.ai/papers/10.1038/s41434-021-00232-2
The paper
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021). Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy? Gene Therapy. https://doi.org/10.1038/s41434-021-00232-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.